The New Market Access Playbook

For decades, the market access playbook read like a simple recipe. Run a clean Phase 3. Beat the comparator. Package the story. Sign the contracts. Launch. If your molecule was clinically better, or even just clinically different in a defensible way, you’d earn a formulary spot, and the rest was execution. That world is gone.

The healthcare landscape has changed, and the traditional market access playbook is no longer enough. In this white paper, Petauri examines the forces reshaping access decisions, from payer consolidation and health system influence to Medicare Part D redesign and biosimilar competition. Learn how leading organizations are moving market access earlier in development, building stronger value stories, and preparing for a more complex commercialization environment to improve launch success and long-term product adoption.